FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022149251> ?p ?o ?g. }

• W2022149251 endingPage "d6333" @default.
• W2022149251 startingPage "d6333" @default.
• W2022149251 abstract "<b>Objectives</b> To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. <b>Design</b> Quantitative benefit-harm and economic analyses using a discrete event simulation model to extrapolate the findings of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study to a lifetime horizon. <b>Setting</b> UK National Health Service. <b>Population</b> Cohorts of 50 000 simulated patients at moderate to high risk of stroke with a mean baseline CHADS₂ (Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack) score of 2.1. <b>Main outcome measures</b> Quality adjusted life years (QALYs) gained and incremental cost per QALY of dabigatran compared with warfarin. <b>Results</b> Compared with warfarin, low dose and high dose dabigatran were associated with positive incremental net benefits of 0.094 (95% central range −0.083 to 0.267) and 0.146 (−0.029 to 0.322) QALYs. Positive incremental net benefits resulted for high dose dabigatran in 94% of simulations versus warfarin and in 76% of those versus low dose dabigatran. In the economic analysis, high dose dabigatran dominated the low dose, had an incremental cost effectiveness ratio of £23 082 (€26 700; $35 800) per QALY gained versus warfarin, and was more cost effective in patients with a baseline CHADS₂ score of 3 or above. However, at centres that achieved good control of international normalised ratio, such as those in the UK, dabigatran 150 mg was not cost effective, at £42 386 per QALY gained. <b>Conclusions</b> This analysis supports regulatory decisions that dabigatran offers a positive benefit to harm ratio when compared with warfarin. However, no subgroup for which dabigatran 110 mg offered any clinical or economic advantage over 150 mg was identified. High dose dabigatran will be cost effective only forpatients at increased risk of stroke or for whom international normalised ratio is likely to be less well controlled." @default.
• W2022149251 created "2016-06-24" @default.
• W2022149251 creator A5006847944 @default.
• W2022149251 creator A5021865444 @default.
• W2022149251 creator A5070376982 @default.
• W2022149251 creator A5084825146 @default.
• W2022149251 date "2011-10-31" @default.
• W2022149251 modified "2023-10-06" @default.
• W2022149251 title "Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses" @default.
• W2022149251 cites W1515782956 @default.
• W2022149251 cites W1967889750 @default.
• W2022149251 cites W1982179895 @default.
• W2022149251 cites W1989446427 @default.
• W2022149251 cites W1998532326 @default.
• W2022149251 cites W1999468381 @default.
• W2022149251 cites W2018796325 @default.
• W2022149251 cites W2025210971 @default.
• W2022149251 cites W2029640576 @default.
• W2022149251 cites W2032847824 @default.
• W2022149251 cites W2051910688 @default.
• W2022149251 cites W2057926962 @default.
• W2022149251 cites W2058719728 @default.
• W2022149251 cites W2059533196 @default.
• W2022149251 cites W2062003960 @default.
• W2022149251 cites W2066157763 @default.
• W2022149251 cites W2071399101 @default.
• W2022149251 cites W2083035480 @default.
• W2022149251 cites W2083828641 @default.
• W2022149251 cites W2084643544 @default.
• W2022149251 cites W2095647706 @default.
• W2022149251 cites W2095783086 @default.
• W2022149251 cites W2097112083 @default.
• W2022149251 cites W2101384748 @default.
• W2022149251 cites W2103053426 @default.
• W2022149251 cites W2103751952 @default.
• W2022149251 cites W2113446992 @default.
• W2022149251 cites W2115606499 @default.
• W2022149251 cites W2118882175 @default.
• W2022149251 cites W2120865130 @default.
• W2022149251 cites W2122723968 @default.
• W2022149251 cites W2127032706 @default.
• W2022149251 cites W2127448855 @default.
• W2022149251 cites W2130909191 @default.
• W2022149251 cites W2136065216 @default.
• W2022149251 cites W2136489990 @default.
• W2022149251 cites W2140188631 @default.
• W2022149251 cites W2157459435 @default.
• W2022149251 cites W2162810133 @default.
• W2022149251 cites W2164615468 @default.
• W2022149251 cites W3135185800 @default.
• W2022149251 cites W3202777792 @default.
• W2022149251 cites W2582765681 @default.
• W2022149251 doi "https://doi.org/10.1136/bmj.d6333" @default.
• W2022149251 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3204867" @default.
• W2022149251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22042753" @default.
• W2022149251 hasPublicationYear "2011" @default.
• W2022149251 type Work @default.
• W2022149251 sameAs 2022149251 @default.
• W2022149251 citedByCount "148" @default.
• W2022149251 countsByYear W20221492512012 @default.
• W2022149251 countsByYear W20221492512013 @default.
• W2022149251 countsByYear W20221492512014 @default.
• W2022149251 countsByYear W20221492512015 @default.
• W2022149251 countsByYear W20221492512016 @default.
• W2022149251 countsByYear W20221492512017 @default.
• W2022149251 countsByYear W20221492512018 @default.
• W2022149251 countsByYear W20221492512019 @default.
• W2022149251 countsByYear W20221492512020 @default.
• W2022149251 countsByYear W20221492512021 @default.
• W2022149251 countsByYear W20221492512022 @default.
• W2022149251 countsByYear W20221492512023 @default.
• W2022149251 crossrefType "journal-article" @default.
• W2022149251 hasAuthorship W2022149251A5006847944 @default.
• W2022149251 hasAuthorship W2022149251A5021865444 @default.
• W2022149251 hasAuthorship W2022149251A5070376982 @default.
• W2022149251 hasAuthorship W2022149251A5084825146 @default.
• W2022149251 hasBestOaLocation W20221492511 @default.
• W2022149251 hasConcept C112930515 @default.
• W2022149251 hasConcept C126322002 @default.
• W2022149251 hasConcept C127413603 @default.
• W2022149251 hasConcept C151730666 @default.
• W2022149251 hasConcept C164705383 @default.
• W2022149251 hasConcept C2776301958 @default.
• W2022149251 hasConcept C2778810321 @default.
• W2022149251 hasConcept C2779161974 @default.
• W2022149251 hasConcept C2779343474 @default.
• W2022149251 hasConcept C2780645631 @default.
• W2022149251 hasConcept C2908647359 @default.
• W2022149251 hasConcept C3019080777 @default.
• W2022149251 hasConcept C64332521 @default.
• W2022149251 hasConcept C71924100 @default.
• W2022149251 hasConcept C78519656 @default.
• W2022149251 hasConcept C86803240 @default.
• W2022149251 hasConcept C99454951 @default.
• W2022149251 hasConceptScore W2022149251C112930515 @default.
• W2022149251 hasConceptScore W2022149251C126322002 @default.
• W2022149251 hasConceptScore W2022149251C127413603 @default.
• W2022149251 hasConceptScore W2022149251C151730666 @default.

• next